Should All Patients with Serous and Clear Cell Endometrial Carcinoma Receive Adjuvant Chemotherapy? | Zendy

Todd Boren | Zendy; David S. Miller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Should All Patients with Serous and Clear Cell Endometrial Carcinoma Receive Adjuvant Chemotherapy?

Author(s) -

Todd Boren,

David S. Miller

Publication year - 2010

Publication title -

women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.363

H-Index - 39

eISSN - 1745-5065

pISSN - 1745-5057

DOI - 10.2217/whe.10.64

Subject(s) - medicine , endometrial cancer , oncology , regimen , taxane , clear cell carcinoma , stage (stratigraphy) , clinical trial , chemotherapy , clear cell , serous fluid , gynecology , carcinoma , cancer , breast cancer , biology , paleontology

Uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) represent two rare subtypes that have an increased risk of recurrence and worse overall survival compared with the more common endometrioid endometrial cancers. Meaningful data in the form of prospective randomized trials is lacking for both advanced and early-stage UPSC and UCCC. Data extrapolated from prospective trials in advanced endometrioid endometrial cancer and retrospective trials on early-stage UPSC suggest that adjuvant platinum and taxane-based chemotherapy may provide a survival benefit for these patients. Future trials specifically examining UPSC and UCCC are needed to elucidate the optimal treatment regimen for these patients. Given the current data, the option of chemotherapy should be considered in treatment-planning discussions for all patients with UPSC and UCCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research